Company Profile

Company Description

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute and chronic inflammatory and immunologic diseases. The company specializes in calcium release-activated calcium (CRAC) channel inhibitors, targeting conditions such as acute pancreatitis and organ transplant rejection. Its lead candidate, Auxora, aims to address severe inflammatory responses by modulating immune cell activity. With a strong emphasis on scientific innovation, the company collaborates with leading researchers to advance its pipeline. CalciMedica's work holds potential for improving outcomes in critical care and autoimmune disorders, offering hope for patients with limited treatment options. The company operates with a commitment to rigorous clinical development and patient-centric solutions.